Group One Trading
PRME icon

Group One Trading’s Prime Medicine PRME Stock Holding History

Group One Trading’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314K Sell
85,200
-83,300
-49% -$277K ﹤0.01% 3912
2026
Q1 		$586K Buy
168,500
+13,800
+9% +$52.5K ﹤0.01% 3196
2025
Q4 		$537K Sell
154,700
-20,200
-12% -$89.9K ﹤0.01% 3429
2025
Q3 		$969K Sell
174,900
-177,200
-50% -$720K ﹤0.01% 3066
2025
Q2 		$870K Buy
352,100
+322,500
+1,090% +$497K ﹤0.01% 2900
2025
Q1 		$58.9K Buy
29,600
+25,600
+640% +$65.3K ﹤0.01% 5030
2024
Q4 		$11.7K Sell
4,000
-226,800
-98% -$796K ﹤0.01% 6022
2024
Q3 		$893K Buy
230,800
+229,800
+22,980% +$1.06M ﹤0.01% 2397
2024
Q2 		$5.14K Buy
1,000
+900
+900% +$5.46K ﹤0.01% 5942
2024
Q1 		$700 Sell
100
-100
-50% -$758 ﹤0.01% 6696
2023
Q4 		$1.77K Buy
+200
New +$1.54K ﹤0.01% 6857

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Group One Trading's PRME Position: Q2 2026 in Review

Group One Trading sold out of Prime Medicine (PRME) in Q2 2026, closing a stake of 24,766 shares — an estimated $82.3K sold.

Group One Trading first reported a position in PRME in Q2 2024 and held it in 3 quarters. The position peaked at $358K in Q4 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Group One Trading reported no remaining Prime Medicine position as of Q2 2026 after selling out during the quarter.
  • Group One Trading sold 24,766 Prime Medicine shares in Q2 2026, an estimated $82.3K.
  • Group One Trading first reported a position in Prime Medicine in Q2 2024 and held it in 3 quarters.
  • Group One Trading's Prime Medicine position peaked at $358K in Q4 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.